Cargando…
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
BACKGROUND: Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signal regulatory protein alpha (SIRPα). Activation of macro...
Autores principales: | Tahk, Siret, Vick, Binje, Hiller, Björn, Schmitt, Saskia, Marcinek, Anetta, Perini, Enrico D., Leutbecher, Alexandra, Augsberger, Christian, Reischer, Anna, Tast, Benjamin, Humpe, Andreas, Jeremias, Irmela, Subklewe, Marion, Fenn, Nadja C., Hopfner, Karl-Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477557/ https://www.ncbi.nlm.nih.gov/pubmed/34579739 http://dx.doi.org/10.1186/s13045-021-01163-6 |
Ejemplares similares
-
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020) -
A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape
por: Kellner, Markus, et al.
Publicado: (2022) -
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021) -
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)